Schizophrenia Clinical Trial
Official title:
A Randomized Controlled Trial Comparing Joint Crisis Plans With Crisis Cards for People With Bipolar Disorders, Schizophrenia and Other Psychotic Disorders to Reduce Involuntary Admission and Coercive Measures.
This randomized clinical trial compares the influence of joint crisis plans (JCP) or crisis cards to reduce psychiatric coercion for people with severe and often recurring mental illnesses like schizophrenia, bipolar disorder or schizoaffective disorder. Both interventions will be carried out as an integrated part of otherwise standard psychiatric in-patient and out-patient care in psychiatric units specializing in the acute or non-acute treatment of mentioned mental illnesses.
Single open-label randomised clinical trial with parallel control groups.
The intervention group "joint crisis plan" benefits from a joint crisis plan in addition to
the usual in-patient care. The active control group "crisis card" benefits from the crisis
card in addition to the usual in-patient or out-patient care.
OBJECTIVES:
The study aims at evaluating the effectiveness of a joint crisis plan compared with crisis
cards regarding the reduction of coercive measure in the following hospital admission.
PROCEDURES:
A weekly screening of all service users regarding eligibility will be carried out. Each
eligible person will be approached by a trained staff member of the unit and invited to
participate in the study, but not before the patient is capable of consenting to treatment.
After informed consent has been obtained, a staff member conducts a baseline assessment using
the Global Assessment of Functioning (GAF), the Clinical Global Impression (CGI) and the
Brief Psychiatric Rating Scale (BPRS). Then participants will be randomly allocated to either
intervention or control group and specific intervention will be carried out. Joint crisis
plan: Due to the duration of the process, the facilitated preparations for the negotiation
session should start immediately. For those treated as in-patients, intervention should be
finish before their release from the hospital. Crisis card: The in-patient and the attending
physician fill out a crisis card together when the patient is to be released from the clinic.
Out-patient prepare a crisis card together with their clinic physician during a routine visit
to the clinic doctor's office. After the 12-month-follow-up-period participants will be
assessed again regarding received psychiatric in-patient care and experienced coercive
measures in any clinic during this period. Additionally, the patient's case files are
examined for documented coercive measures.
HYPOTHESES:
The primary hypothesis to be tested is whether JCPs significantly reduce the average of
involuntarily spent days of hospitalization during the 12 month follow-up period, compared
with the control group receiving crisis cards.
Secondary hypotheses will be to determine whether compared with the control condition, JCP
use will result in improvements regarding other common coercive incidents: involuntary
medication, isolation, and physical restraint.
SAMPLE SIZE CALCULATION:
The necessary sample size regarding the primary outcome criterion "days in accommodation" was
calculated utilizing routine data of a random sample (N = 20) of in-patients. The following
inclusion criteria were used for the population of patients:
- relevant period: 1st of January to 31st of December 2016
- at least one acute psychiatric inpatient hospital stay with admission and discharge in
2016 (UKE: station PEAG)
- minimum length of in-patient treatment 3 days
- documented ICD-10 diagnosis: F2*/F3*
A zero-inflated negative binomial regression was calculated to obtain the estimator for the
average number of days in accommodation (15.69) and the estimator for the overdispersion
(0.49). The sample size calculation was carried out with a type I error of 5% (two-tailed)
and a power of 80%.
The calculation was carried out with PASS 2008 (NCSS, LLC Kaysville, Utah). It led to a
sample size of 151 patients per group (a total of 302 patients). Taking withdrawal and
follow-up loss of combined approx. 20% into account an initial sample size of 374 patients
(187 per group) will be necessary.
STATISTICAL ANALYSIS:
In order to address primary and secondary objectives, an intention-to-treat analysis (ITT)
will be calculated as a zero-inflated negative binomial regression. The group variable (JCP
vs. crisis card) is included as a fixed effect into the model. Additionally, a per-protocol
analysis (PP) will be performed to examine the actual interventional effect.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |